NSE filing, NSE: AIMTRON. Summary written from the filing by ALFA Finder's alert engine.
Aimtron Electronics Ltd: key numbers
- Share price
- ₹1,945.00
- Market cap
- ₹4,172 Cr
- Revenue (annual)
- ₹301.2 Cr
- Net profit (annual)
- ₹45.97 Cr
- P/E (TTM)
- 90.8×Sector 45.0×
- Promoter holding
- 68.07%
- FII holding
- 0.33%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aimtron Electronics Ltd
All →Aimtron Electronics Results Update
Aimtron Electronics reported 83% revenue growth for H1 FY27, reaching INR 224.71 Crore. The company's consolidated unexecuted order book stood at INR 733.27 Crore.
- Value
- ₹224.7 Cr
- Order book
- ₹733.3 Cr
Aimtron Electronics H1 FY27 Results: Net Profit ₹34.8 Cr, Up 71.4% YoY
Aimtron Electronics Ltd reported revenue from operations of ₹224.7 Cr (+83.3% YoY) and net profit of ₹34.8 Cr (+71.4% YoY) for H1 FY27.
- Key figure
- Net profit ₹34.8 Cr · +71.4% YoY
Aimtron Electronics Preferential Issue
Aimtron Electronics shareholders approved a ₹205 Cr preferential equity issue at their EGM. Proceeds will fund strategic expansion, working capital, and general corporate purposes.
- Value
- ₹205.0 Cr
Aimtron Electronics Preferential Issue
Aimtron Electronics issued a corrigendum to its EGM notice scheduled for October 22, 2026, clarifying details regarding the proposed preferential issue of convertible warrants.
Aimtron Electronics Annual General Meeting
Aimtron Electronics Limited has announced October 14, 2026, as the cut-off date for e-voting entitlement. An Extra-Ordinary General Meeting is scheduled for October 22, 2026.
Aimtron Electronics Annual General Meeting
Aimtron Electronics Limited has issued a notice for an Extraordinary General Meeting on October 22, 2026. Shareholders will consider a preferential issue of equity shares worth Rs. 205.00 Crore.
- Value
- ₹205.0 Cr
Other other announcement announcements
All →Glenmark Pharmaceuticals Other Announcement
Glenmark's partner IGI will present updated Phase 1 clinical data for ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma at the 68th ASH Annual Meeting. The presentation is scheduled for December 12, 2026.
Vineet Laboratories Other Announcement
Vineet Laboratories' board appointed SVRL & Co. as statutory auditors, subject to shareholder approval. The five-year term runs from the 10th AGM to the 16th AGM.
Physicswallah Other Announcement
Physicswallah's IPO monitoring report flags a deviation from offer objects for the quarter ended September 30, 2026. The diverted funds were restored on October 30, 2026.
Gujarat Kidney and Super Speciality Other Announcement
Gujarat Kidney filed Brickwork's monitoring agency report for the quarter ended September 30, 2026. It confirms no deviation from the IPO fund-utilisation objects.
PDS Other Announcement
PDS Limited submitted the CRISIL Ratings monitoring agency report for the quarter ended September 30, 2026. It confirms no deviation in the utilisation of its QIP proceeds.
Schaeffler India Other Announcement
Schaeffler India disclosed that CRISIL ESG Ratings assigned it an ESG Score of 67 on an unsolicited basis. The company did not engage or subscribe to the rating provider.